Genprex Inc (GNPX)

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming...

Form 8-K - Current report

Genprex to Participate at BIO International Convention 2026

Genprex to Participate at BIO International Convention 2026 PR Newswire AUSTIN, Texas, June 17, 2026...

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO...

Form 8-K - Current report

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and...